Linear mixed regression models of factors influencing the effect of UFH (anti-Xa, aPTT, ACT)
| UFH assay . | Determinant . | b . | 95% CI . | P . |
|---|---|---|---|---|
| Anti-Xa (U/mL) | UFH dose group (high vs low) | 0.66 | 0.42; 0.89 | <.001 |
| Age (per year) | 0.02 | 0.01; 0.04 | .001 | |
| Baseline antithrombin (per 0.1 U/mL) | 0.06 | 0.02; 0.10 | .003 | |
| Sample time point (30, 60, 90 min) | −0.16 | −0.21; −0.10 | <.001 | |
| Interaction UFH dose group × sample time point | −0.08 | −0.01; −0.15 | .019 | |
| aPTT (s) | Interaction UFH dose group × sample time point | 42 | 17; 68 | .001 |
| Age (per year) | 3 | 1; 5 | .003 | |
| Sex (female) | 25 | 45.2; 4.9 | .015 | |
| Baseline aPTT (per second) | 2 | 1.8; 4 | .004 | |
| ACT (s) | UFH dose group (high vs low) | 190 | 117; 263 | <.001 |
| Baseline ACT (per second) | 1 | 0; 2 | .009 | |
| Sample time point (30, 60, 90 min) | −55 | −70; −39 | <.001 | |
| Interaction UFH dose group × sample time point | −36 | −57; −16 | .001 |
| UFH assay . | Determinant . | b . | 95% CI . | P . |
|---|---|---|---|---|
| Anti-Xa (U/mL) | UFH dose group (high vs low) | 0.66 | 0.42; 0.89 | <.001 |
| Age (per year) | 0.02 | 0.01; 0.04 | .001 | |
| Baseline antithrombin (per 0.1 U/mL) | 0.06 | 0.02; 0.10 | .003 | |
| Sample time point (30, 60, 90 min) | −0.16 | −0.21; −0.10 | <.001 | |
| Interaction UFH dose group × sample time point | −0.08 | −0.01; −0.15 | .019 | |
| aPTT (s) | Interaction UFH dose group × sample time point | 42 | 17; 68 | .001 |
| Age (per year) | 3 | 1; 5 | .003 | |
| Sex (female) | 25 | 45.2; 4.9 | .015 | |
| Baseline aPTT (per second) | 2 | 1.8; 4 | .004 | |
| ACT (s) | UFH dose group (high vs low) | 190 | 117; 263 | <.001 |
| Baseline ACT (per second) | 1 | 0; 2 | .009 | |
| Sample time point (30, 60, 90 min) | −55 | −70; −39 | <.001 | |
| Interaction UFH dose group × sample time point | −36 | −57; −16 | .001 |
b, unstandardized partial correlation coefficient; CI, confidence interval.